EUCTR2007-001776-36-GB进行中（未招募）1 期
A randomized multicenter study evaluating efficacy, safety, tolerability and pharmacokinetics of AEB071 combined with tacrolimus or mycophenolate mofetil (MMF) vs. a tacrolimus-based control regimen in de novo liver transplant recipients.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Ability and willingness to provide written informed consent and adhere to study regimen
- •Male and female patients of any race, 18 years or older
- •De novo recipients of a primary orthotopic liver transplant from a deceased donor
- •HCV-positive and HCV-negative recipients
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Recipient criteria
- •Prior organ/cellular transplants or of multiple organ transplants
- •Anti-HIV-positive. Laboratory results obtained within 6 months prior to transplantation are acceptable
- •ABO incompatible allograft
- •MELD-score > 35 within 1 month prior transplantation
- •Serum creatinine of = 3.0 mg/dL ( = 265 µmol/L) or on renal replacement therapy > 1 week
- •Donor criteria:
- •Donor age < 12 years
- •Partial (split) liver allograft
- •Living donor liver transplantation
- •Cardiac death donors (DCD) / non-heartbeating donors
- •HIV positive donors
- •HCV positive donors into HCV negative recipients
- •HBsAg positive donors
- •Cold ischemic time of >15 hours
- •Macrosteatosis > 50%
- •Medical history & concomitant disease criteria of recipient:
- •Acute liver failure (UNOS I, T1)
- •Hepatocellular carcinoma (HCC) that exceeds the Milan criteria (1 nodule =5 cm, 2-3 nodules all <3 cm) at the time of transplantation
- •Past or present malignancy within the past 5 years (other than excised basal cell carcinoma and HCC satisfying the Milan criteria.
- •Patients in whom biopsy cannot be safely performed (e.g. coagulopathy without the option of transjugular biopsy)
- •Severe active infection considered by the investigator to be unsafe for the study
- •(Co-)medication related criteria:
- •Patients with antibody induction therapy other than specified in the protocol (e.g. basiliximab allowed in only one of the study arms) or who receive any other immunosuppressive therapy not defined in the protocol
- •History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures
- •Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half lives of enrollment, whichever is longer
- •Patients who are requiring the administration of strongly interacting drugs of the cytochrome P450 3A4 system (see Protocol Appendix 2)
- •Cardiac safety criteria:
- •Patients requiring drugs with QT-prolonging properties (e.g. antiarrhythmic drugs, such as amiodarone, sotalol, dofetilide, quinidine, procainamide, disopyramide)
- •Patients with QTc > 470 msec (females) and > 450 msec (males), respectively, at screening, or in at least two of the triplicate ECG-tracings at baseline (Fridericia correction), long QT-syndrome (own or with a family history) or with a family history of sudden unexplained cardiac death
- •Patients with left branch bundle block (LBBB) or who experienced, during the previous 6 months, hospitalization for heart failure of cardiac etiology, or significant and persistent left-ventricular dysfunction (LVEF < 40%)
- •Patients with a history, in the preceding 3 months, of significant and persistent arrhythmias such as ventricular fibrillation or tachycardia, or atrial fibrillation or flutter
- •Patients with symptomatic coronary artery disease
- •General criteria:
- •Existence of any surgical, medical or mental conditions, other than the cur
研究者
相似试验
进行中（未招募）
不适用
A randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of AEB071 combined with tacrolimus or mycophenolate mofetil (MMF) vs a tacrolimus-based control regimen in de novo liver transplant recipients - NDde novo liver transplant recipientsMedDRA version: 9.1Level: LLTClassification code 10024714Term: Liver transplantEUCTR2007-001776-36-ITOVARTIS FARMA320
招募中
不适用
Home-based and group cognitive intervention programs in amnestic mild cognitive impairmentMental and behavioral disordersKCT0000328Inha University Hospital270
进行中（未招募）
不适用
Enterosgel® in the treatment of atopic dermatitis in adultsSkin and Connective Tissue DiseasesAtopic dermatitisISRCTN12307286Enteromed Ltd44
进行中（未招募）
不适用
Multicenter randomized study to assess the efficacy and the safety of two therapeutic regimens(high dose of imiglucerase versus co-administration of imiglucerase and miglustat) in type I Gaucher disease patients who have not responded to previous treatment with low dose imiglucerase - NDMedDRA version: 9.1Level: LLTClassification code 10018048Term: Gaucher's diseaseGAUCHER diseaseEUCTR2007-005516-61-ITISTITUTO GIANNINA GASLINI
招募中
2 期
A Clinical Trial to study the effects of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral ConjunctivitisCTRI/2012/11/003145ovaBay Pharmaceutical Inc440